Autopsy report · NCT00354523

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

“Study closed following Phase I portion, insufficient activity to continue to Phase II.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 7 months after it had already started.
• Ran for about 8 years 8 months before it stopped.
• 21 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Solid Tumor; Thyroid Cancer

Interventions

Capecitabine (Xeloda); DTIC-Dome (Dacarbazine); Gleevec (Imatinib Mesylate)

Participants

21

Sites

1

Countries

United States

Trials that died the same way

• A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
  “This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.” (72% match in meaning)
• Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
  “After completion of Phase I, it was decided not to initiate Phase II of the study.” (72% match in meaning)
• Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
  “Due to lack of funding, phase II of study was not completed.” (67% match in meaning)
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
  “This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” (66% match in meaning)
• Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
  “business reasons-Phase 2/Part B not conducted. Study terminated after last patient enrolled in Phase 1/Part A” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.